Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer. "This is the first prospective study to evaluate the treatment of venous thromboembolism (VTE) or blood clots in cancer patients and is a potentially practice-changing clinical trial," said principal investigator Dr. Myra Barginear, M.D., of The North Shore-LIJ Health System in New York, U.S.A. The inferior vena cava is a large blood vessel in the abdomen that carries blood from the lower parts of the body back to the heart. A thin-mesh IVC filter can be placed in the inferior vena cava to prevent blood clots, or VTEs, from reaching the heart.
In the study, sixty-four patients with deep venous thrombosis (86%) and/or pulmonary embolism (55%) received fondaparinux. About half of patients received only fondaparinux, while the other half received fondaparinux in conjunction with an IVCF.
The median survival for patients receiving only fondaparinux was 493 days, compared with 266 days for patients on fondaparinux plus an IVCF. Meanwhile, a median 52% of patients on fondaparinux alone experienced a complete resolution of VTEs, compared with 45% of patients on fondaparinux plus IVCF.
The study suggests that there is no benefit from costly and invasive IVCF placement in patients who are receiving fondaparinux. The results also support future randomized trials to compare VTE resolution rates achieved with fondaparinux with low molecular weight heparin, another class of anticoagulant medication.
Source: International Association for the Study of Lung Cancer
Articles on the same topic
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to dateThu, 7 Jul 2011, 8:33:38 UTC
- Endosonography followed by surgical staging improves quality of life, according to ASTER studyThu, 7 Jul 2011, 8:33:26 UTC
- TGen presents lung cancer studies at Amsterdam conferenceThu, 7 Jul 2011, 7:33:39 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersWed, 6 Jul 2011, 8:33:41 UTC
- Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDAWed, 6 Jul 2011, 8:33:31 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009Wed, 6 Jul 2011, 8:33:06 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection rateWed, 6 Jul 2011, 8:32:53 UTC
- First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conferenceWed, 6 Jul 2011, 7:35:20 UTC
- Celecoxib may prevent lung cancer in former smokersWed, 6 Jul 2011, 4:33:12 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy Tue, 5 Jul 2011, 9:02:35 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation ConsortiumTue, 5 Jul 2011, 9:02:25 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersTue, 5 Jul 2011, 9:02:15 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyTue, 5 Jul 2011, 9:02:06 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsTue, 5 Jul 2011, 9:01:57 UTC
Other sources
- Endosonography followed by surgical staging improves quality of life, according to new studyfrom Science DailyThu, 7 Jul 2011, 14:30:50 UTC
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to datefrom PhysorgThu, 7 Jul 2011, 11:00:24 UTC
- Endosonography followed by surgical staging improves quality of life, according to ASTER studyfrom PhysorgThu, 7 Jul 2011, 11:00:22 UTC
- Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinuxfrom PhysorgThu, 7 Jul 2011, 11:00:21 UTC
- TGen presents lung cancer studies at Amsterdam conferencefrom PhysorgThu, 7 Jul 2011, 8:01:37 UTC
- Celecoxib may prevent lung cancer in former smokersfrom Science DailyWed, 6 Jul 2011, 20:32:45 UTC
- Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDAfrom PhysorgWed, 6 Jul 2011, 14:30:50 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersfrom PhysorgWed, 6 Jul 2011, 14:30:49 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009from PhysorgWed, 6 Jul 2011, 14:01:53 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection ratefrom PhysorgWed, 6 Jul 2011, 14:01:45 UTC
- Celecoxib may prevent lung cancer in former smokersfrom PhysorgWed, 6 Jul 2011, 7:30:43 UTC
- First whole-genome lung cancer study set for conferencefrom PhysorgWed, 6 Jul 2011, 7:30:31 UTC
- Drug may prevent lung cancer in former smokersfrom Science BlogWed, 6 Jul 2011, 4:30:47 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom Science DailyTue, 5 Jul 2011, 14:31:06 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom Science DailyTue, 5 Jul 2011, 14:31:05 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom Science DailyTue, 5 Jul 2011, 14:31:04 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom PhysorgTue, 5 Jul 2011, 9:00:23 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:21 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:20 UTC